Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/36051
Tipo
ArtículoDerechos de autor
Acceso restringido
Colecciones
Metadatos
Mostrar el registro completo del ítem
PHARMACOLOGICAL AND PHYSICOCHEMICAL PROFILE OF ARYLACETAMIDES AS TOOLS AGAINST HUMAN CANCERS
Modelo Xenoenxerto
Parâmetros Fisiológicos
Efeitos Ansiolíticos
Animal Comportamental
Xenograft Model
Physiological Parameters
Anxiolytic-like Effects
Behavioral Animal
Autor
Ferreira, Paulo Michel Pinheiro
Machado, Kátia da Conceição
Lavorato, Stefânia Neiva
Oliveira, Fátima de Cássia Evangelista de
Silva, Jurandy do Nascimento
Almeida, Antonia Amanda Cardoso de
Santos, Luciano de Souza
Silva, Valdenizia Rodrigues
Bezerra, Daniel Pereira
Soares, Milena Botelho Pereira
Pessoa, Cláudia
Moraes Filho, Manoel Odorico de
Ferreira, José Roberto de Oliveira
Sousa, João Marcelo de Castro E
Maltarollo, Vinícius Gonçalves
Alves, Ricardo José
Machado, Kátia da Conceição
Lavorato, Stefânia Neiva
Oliveira, Fátima de Cássia Evangelista de
Silva, Jurandy do Nascimento
Almeida, Antonia Amanda Cardoso de
Santos, Luciano de Souza
Silva, Valdenizia Rodrigues
Bezerra, Daniel Pereira
Soares, Milena Botelho Pereira
Pessoa, Cláudia
Moraes Filho, Manoel Odorico de
Ferreira, José Roberto de Oliveira
Sousa, João Marcelo de Castro E
Maltarollo, Vinícius Gonçalves
Alves, Ricardo José
Afiliación
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil / Federal University of Western Bahia. Center of Biological Sciences and Health. Barreiras, BA, Brazil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
State University of Alagoas. School of Medical Sciences. Maceió, AL, Brazil.
Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil / Federal University of Piauí. Department of Biology. Picos, PI, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil / Federal University of Western Bahia. Center of Biological Sciences and Health. Barreiras, BA, Brazil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Federal University of Piauí. Laboratory of Experimental Cancerology. Department of Biophysics and Physiology. Teresina, PI, Brazil / Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
Federal University of Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Fortaleza, CE, Brazil.
State University of Alagoas. School of Medical Sciences. Maceió, AL, Brazil.
Federal University of Piauí. Postgraduate Programs in Pharmaceutical Sciences and Biotechnology. Teresina, PI, Brazil / Federal University of Piauí. Department of Biology. Picos, PI, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil.
Federal University of Minas Gerais. Faculty of Pharmacy. Department of Pharmaceutical Products. Belo Horizonte, MG, Brazil.
Resumen en ingles
Arylacetamides are widely used as synthetic intermediates to obtain medicinal substances. This work evaluated in vitro antiproliferative activity of ten 2-Chloro-N-arylacetamides on human normal and cancer cells and detailed in vivo toxicological and anticancer investigations. Initially, cytotoxic colorimetric assays were performed using tumor lines, peripheral blood mononuclear cells (PBMC) and erythrocytes. Compounds 2, 3 and 4 were tested for acute toxicity (50, 150 and 300 mg/kg) and for subacute antitumoral capacity in HCT-116 colon carcinoma-bearing xenograft mice for 15 days at 25 mg/kg/day. Most compounds revealed cytotoxic action on tumor lines and PBMC, but activity on human erythrocytes were not detected. Molecular dipole moment, lipophilicity and electronic constant of aryl substituents had effects upon in vitro antiproliferative capacity. More common in vivo acute behavioral signals with compounds 2, 3 and 4 were muscle relaxation, reduction of spontaneous locomotor activity and number of entries in closed arms and increased number of falls andtime spent in open arms, suggesting diazepam-like anxiolytic properties. Decrease of grabbing strength and overall activity were common, but palpebral ptosis and deaths occurred at 300 mg/kg only. Compounds 2 and 3 reduced colon carcinoma growth (21.2 and 27.5%, respectively, p < 0.05) without causing apparent signals of organ-specific toxicity after subacute exposure. The structural chemical simplicity of arylacetamides make them cost-effective alternatives and justifies further improvements to enhance activity, selectivity and the development of pharmaceutical formulations.
Palabras clave en portugues
Carcinoma de CólonModelo Xenoenxerto
Parâmetros Fisiológicos
Efeitos Ansiolíticos
Animal Comportamental
Palabras clave en ingles
Colon CarcinomaXenograft Model
Physiological Parameters
Anxiolytic-like Effects
Behavioral Animal
Compartir